In recent trading session, Checkpoint Therapeutics Inc (NASDAQ:CKPT) saw 0.5 million shares changing hands at last check today with its beta currently measuring 1.36. Company’s recent per share price level of $3.60 trading at $0.23 or 6.97% at last check today assigns it a market valuation of $176.04M. That most recent trading price of CKPT’s stock is at a discount of -25.0% from its 52-week high price of $4.50 and is indicating a premium of 61.67% from its 52-week low price of $1.38. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 3.51 million shares which gives us an average trading volume of 1.29 million if we extend that period to 3-months.
For Checkpoint Therapeutics Inc (CKPT), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of 0 in the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Checkpoint Therapeutics Inc (NASDAQ:CKPT) trade information
Upright in the green today for gaining 6.97%, in the last five days CKPT remained trading in the red while hitting it’s week-highest on Wednesday, 12/18/24 when the stock touched $3.60 price level, adding 18.92% to its value on the day. Checkpoint Therapeutics Inc’s shares saw a change of 57.42% in year-to-date performance and have moved -1.77% in past 5-day. Checkpoint Therapeutics Inc (NASDAQ:CKPT) showed a performance of 6.65% in past 30-days. Number of shares sold short was 5.56 million shares which calculate 5.7 days to cover the short interests.
Checkpoint Therapeutics Inc (CKPT) estimates and forecasts
Statistics highlight that Checkpoint Therapeutics Inc is scoring comparatively higher than the scores of other players of the relevant industry. The company added 73.31% of value to its shares in past 6 months, showing an annual growth rate of 71.29% while that of industry is 17.40. Apart from that, the company came raising its revenue forecast for fiscal year 2024. This year revenue growth is estimated to fall -76.70% from the last financial year’s standing.
3 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 10.33k for the same. And 1 analysts are in estimates of company making revenue of 4.53M in the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 26.32% during past 5 years.
Checkpoint Therapeutics Inc (NASDAQ:CKPT)’s Major holders
Insiders are in possession of 15.52% of company’s total shares while institution are holding 13.91 percent of that, with stock having share float percentage of 16.47%. Investors also watch the number of corporate investors in a company very closely, which is 13.91% institutions for Checkpoint Therapeutics Inc that are currently holding shares of the company.
On the other hand, Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund are the top two Mutual Funds which own company’s shares. As of Sep 30, 2024, the former fund manager was holding 1.09 shares of worth $3.97 million or 2.27% of the total outstanding shares. The later fund manager was in possession of 265.74 shares on Sep 30, 2024, making its stake of worth around $0.97 million in the company or a holder of 0.55% of company’s stock.
